Day One Biopharmaceuticals (NASDAQ:DAWN) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN) in a report issued on Wednesday, Benzinga reports. They currently have a $50.00 price target on the stock. HC Wainwright also issued estimates for Day One Biopharmaceuticals’ FY2024 earnings at ($2.79) EPS, FY2025 earnings at ($2.43) EPS, FY2026 earnings at ($1.34) EPS, FY2027 earnings at $0.15 EPS and FY2028 earnings at $1.87 EPS.

DAWN has been the topic of several other reports. Piper Sandler reissued an overweight rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. The Goldman Sachs Group cut their price target on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a buy rating on the stock in a research report on Tuesday, February 27th. Needham & Company LLC boosted their price target on shares of Day One Biopharmaceuticals from $30.00 to $33.00 and gave the stock a buy rating in a research report on Wednesday. Oppenheimer reissued a market perform rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. Finally, JPMorgan Chase & Co. upped their target price on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an overweight rating in a report on Monday, April 22nd. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Day One Biopharmaceuticals presently has an average rating of Moderate Buy and an average price target of $39.33.

Day One Biopharmaceuticals Trading Up 12.9 %

Shares of NASDAQ DAWN opened at $14.92 on Wednesday. The firm has a market cap of $1.30 billion, a PE ratio of -6.27 and a beta of -1.48. Day One Biopharmaceuticals has a 1-year low of $9.67 and a 1-year high of $17.85. The company has a fifty day moving average price of $15.22 and a 200 day moving average price of $13.81.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings results on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.07). Equities research analysts forecast that Day One Biopharmaceuticals will post -2.67 EPS for the current year.

Insider Activity

In other news, General Counsel Adam Dubow sold 3,242 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $49,440.50. Following the sale, the general counsel now directly owns 16,585 shares of the company’s stock, valued at approximately $252,921.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, General Counsel Adam Dubow sold 3,242 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $49,440.50. Following the transaction, the general counsel now owns 16,585 shares in the company, valued at approximately $252,921.25. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Samuel C. Blackman sold 2,258 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $34,434.50. Following the completion of the transaction, the insider now owns 1,244,662 shares in the company, valued at approximately $18,981,095.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 55,781 shares of company stock valued at $883,160. 8.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Hennion & Walsh Asset Management Inc. grew its stake in Day One Biopharmaceuticals by 2.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock valued at $979,000 after buying an additional 1,445 shares during the last quarter. Fisher Asset Management LLC grew its stake in Day One Biopharmaceuticals by 89.0% in the 4th quarter. Fisher Asset Management LLC now owns 68,446 shares of the company’s stock valued at $999,000 after buying an additional 32,238 shares during the last quarter. Wellington Management Group LLP grew its stake in Day One Biopharmaceuticals by 77.7% in the 4th quarter. Wellington Management Group LLP now owns 208,969 shares of the company’s stock valued at $3,051,000 after buying an additional 91,393 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Day One Biopharmaceuticals by 28.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock worth $30,935,000 after purchasing an additional 472,654 shares in the last quarter. Finally, Quintet Private Bank Europe S.A. grew its position in shares of Day One Biopharmaceuticals by 43.2% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after purchasing an additional 1,000 shares in the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.